CooperSurgical terminates InnerDyne agreement:
This article was originally published in Clinica
Executive Summary
CooperSurgical has terminated an agreement to fund the development and clinical trials of InnerDyne's thermal endometrial ablation technology for gynaecological applications. The termination was due to delays in product development which prevented CooperSurgical from fully evaluating the system's clinical safety and efficacy, says the company. CooperSurgical also claims competing endometrial ablation technologies are more likely to gain market approval before InnerDyne's products. Nicholas Pichotta, CooperSurgical's president, says his company is currently pursuing other opportunities to acquire or licence additional products within the surgical gynaecology strategy.